Seeking Alpha

More on Allergan (AGN) Q3: net profit almost flat at $249.4M. Specialty pharmaceuticals sales...

More on Allergan (AGN) Q3: net profit almost flat at $249.4M. Specialty pharmaceuticals sales +8.1%, medical devices -4%. Exploring options for obesity intervention business, including selling it. Guidance: Q4 EPS of $1.18-$1.20 vs consensus of $1.20, revenue of $1.47B-$1.545B vs $1.51B; FY EPS of $4.17-$4.19 vs $4.17 and revenue of $5.695B-$5.77B and $5.82B. (PR)

Check out Seeking Alpha’s new Earnings Center »

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs